The endogenous opioid system comprises ligands from the endorphine, enkephaline, and dynorphine families acting mainly on four opioid receptors, namely m (MORs), d (DORs), k (KOR), and Nociceptin (NOR). While both the analgesic and the addictive pharmacological actions of morphine and its derivatives can solely be accounted for by MORs, DORs have additionally been attributed anxiolytic and anti-depressive properties. Paradoxically, KOR signaling has been associated with both analgesia and allodynia, i.e., pain in response to nonnoxious stimulation, and its activation in brain centers is linked to aversion and the negative component of pain, stress responses, and drug reinstatement (Nation et al., 2018) (Figure 1 ).
The quest for novel opioidergic drugs is a dynamic and topical theme, especially because the well-described adverse effects of conventional opioid analgesics have recently escalated into a major crisis, resulting in thousands of deaths, particularly in the US. Therefore, while the focus has been traditionally on MOR agonists, recent efforts have addressed the therapeutic potential of other receptors as well as their localization in distinct avenues of nociceptive pathways (Maldonado et al., 2018) . Indeed, the abundance of opioid receptor expression throughout the pain pathway makes harnessing them pharmacologically a double-edged sword. Their inhibitory G-protein-mediated actions can elicit potent analgesia on virtually all levels, starting with the terminals of peripheral nerves, the dorsal spinal cord where peripheral afferents transmit nociceptive information to the central neurons, all the way to diverse higher brain; however, the same signaling mechanisms and loci are in play to produce unwanted side effects, most notably centrally evoked respiratory depression, addiction, nausea and peripherally evoked obstipation. Over the past decades, intense efforts have been made to delineate the central and peripheral contributions of analgesics in hope of circumventing central adverse effects by exclusively targeting peripheral receptors. Mice carrying sensory-neuron-specific conditional knockout alleles emerged as a gold standard to investigate these differential contributions. For the first time, it was possible to show that a loss of peripheral cannabinoid receptor 1 leads to a marked attenuation of the analgesic effects of systemically applied cannabinoids (Agarwal et al., 2007) , and a similar strategy was used to demonstrate that DOR agonists have strongly diminished analgesic effect in mice lacking DORs in primary afferents (GaveriauxRuff et al., 2011; Maldonado et al., 2018) . MOR-mediated analgesia was also found to be impaired in inflammatory pain in mice lacking MORs specifically in peripheral sensory neurons (Maldonado et al., 2018) . In contrast, KORs have only recently been in focus. In this issue of Neuron, Ross and colleagues now report on the precise pattern of expression and delineate the functions of KOR in peripheral sensory neurons of the dorsal root ganglia (DRG) of mouse or human origin (Snyder et al., 2018) .
Owing to specificity issues with antibodies, the localization of opioid receptors in diverse types of sensory neurons has indeed been a point of considerable debate. In their study, Snyder et al. (2018) employed an elegant strategy for expression analyses based upon transgenic expression of a fluorescent reporter from the endogenous oprk1 locus, supplemented by state-of-the-art methodologies, such as viral tracing and single-cell PCR. Importantly, expression was further verified in human DRG neurons and validated functionally via electrophysiological recordings and calcium imaging in mice. Their results confirm previous reports on a fairly wide expression of KOR in DRG neurons (Ji et al., 1995) and now interestingly reveal functional KORs in a transcriptionally-distinct population of peptidergic (nociceptive) afferents. These were found to not only target the skin, but to also richly innervate visceral organs, such as the colon and bladder, suggesting important perspectives for controlling visceral pain. Peripheral optogenetic activation of these fibers induced nocifensive behavior, as expected from previous studies on nociceptors. Unexpectedly, they also observed KOR expression in two types of low-threshold mechanoreceptors (LTMRs; typically, non-nociceptive) innervating hair follicles (Figure 1) .
Functionally, activation of KORs led to inhibition of voltage-sensitive calcium channels, consistent with typical G i/omediated signaling, in sensory neurons, a finding which was confirmed in human DRG neurons. Since KOR is targeted throughout the bipolar sensory neuron, one would expect presynaptic inhibition at both peripheral and spinal terminals, which was confirmed in this study (Figure 1) . Indeed, KOR activation inhibited nociceptor sensitization in the periphery and suppressed excitatory neurotransmission between KOR-expressing afferents and spinal neurons in the superficial spinal laminae that process nociceptive information as well as the deep dorsal horn, where non-nociceptive tactile inputs are primarily processed (Figure 1) .
To address the therapeutic relevance of KORs, Snyder et al. (2018) compared a known centrally penetrating KOR agonist with previously reported peripherally restricted KOR agonists. Interestingly, despite the ability to inhibit excitation of peripheral-spinal circuits, at the level of the organismal response in vivo, there was no change in basal nociception upon KOR modulation, except thermal sensitivity, which Snyder et al. (2018) could successfully annotate to centrally expressed KOR. These results largely indicate a lack of tonic inhibition via dynorphin or other opioids acting on KOR. In contrast, in mice with peripheral inflammatory pain, peripherally restricted agonists were able to suppress neurogenic inflammation, inhibit sensitization of colonic afferents, and reduce mechanical hypersensitivity (Figure 1 ). These findings are especially significant because of our limited understanding of the contrasting nature of analgesia and allodynia that have been attributed to dynorphin and KOR activation. Here, KOR expression in the peripheral segment of the nociceptive pathway was systematically and comprehensively analyzed and its functional significance revealed in nociception and inflammatory pain. These results clarify the mechanistic underpinnings of how KORs influence sensory neuron function and clarify the true functional nature of peripheral KORs. This study will undoubtedly stimulate further analyses on potentially relevant aspects that still remain unclear. For instance, while peripheral KOR agonists are capable of suppressing itch, the KOR + population investigated here did not correspond with the known primary itchsensing sensory fibers consisting of the MrgprA3-and SST-expressing populations. It is likely that KOR signaling on non-neuronal cells is involved in acute itch, and additional experiments will help understand the potential contribution of KOR inhibition of neurogenic inflammation toward modulation of itch. Furthermore, given previous studies that similarly report the significance of peripheral MOR and DOR in inflammatory pain and extensive colocalization of MOR, KOR, and DOR, additional mechanistic studies would be helpful to examine the potential influence of the known functionallysignificant interactions between diverse opioid receptor subtypes (Maldonado et al., 2018) . Because all pharmacological agents have caveats and even peripherally restricted agonists are capable of passing the blood-brain barrier in a concentration-dependent manner, the use of genetic models to ablate KOR expression specifically in distinct sensory neuron populations is warranted to truly uncover their functional contributions. Moreover, given that a high density of visceral nociceptive afferents were found to be KOR positive in this study, functional analyses in models of acute and chronic visceral pain hold promise.
Importantly, this work by Ross and colleagues has significant therapeutic implications and further strengthens the case for developing analgesics targeting peripheral KORs (Snyder et al., 2018) . Indeed, although systemic KOR agonists inherently lack the fatal respiratory depression and addictive properties of the of their m counterparts, their effects on the brain leading to increased stress, aversion, and drug reinstatement are significant deterrents to therapeutic use. Recently, new drugs specifically targeting downstream signaling cascades have been proposed as potential new analgesics lacking classical opioid side effects (White et al., 2015) , and comprehensive understanding of the peripheral action of KORs delivered by this study will support further development. However, a number of points warrant more detailed clarification and validation before KOR agonists can really transition into the clinics. Recent studies implicate that specifically targeting peripheral neurons might not solve current problems with opioid therapy as MOR signaling in primary afferents also contributes to the development of morphine tolerance and opioid-induced hyperalgesia (Maldonado et al., 2018 ). These effects would severely limit therapeutic gains, and additional studies are needed to rule out that KOR agonists have similar caveats. Furthermore, it is important to acknowledge that although the notion of peripherally mediated analgesia has been around for more than a decade, very little clinical application has materialized. Despite positive data from animal studies, the exclusive peripheral delivery of opioids failed to induce adequate analgesia in a majority of clinical studies (Nielsen et al., 2015) ; modest effects were only reported upon intraarticular injections in inflamed joints (Kalso et al., 1997) , and especially given the higher perfusion of inflamed tissue, it has remained unclear whether the partial pain relief could actually be accounted for by the periphery. Importantly, the recent development and testing of peripherally restricted m opioidergic drugs has ushered in new hope (Spahn et al., 2017) , suggesting that peripheral opioidergic drugs may yet yield rewarding therapies.
Overall, Snyder et al. (2018) is a remarkable study that advances our understanding of an important, previously less-characterized class of opioid receptors and their contribution to opioid analgesia. In light of the evident treatment crisis with classical m agonists, investigation of other branches of the opioid system is highly timely and will set the stage for testing a new generation of analgesic pharmaceuticals with less potential for abuse and milder side effects.
